Real-World Survival in Patients with Metastatic Melanoma after Discontinuation of Anti-PD-1 Immunotherapy for Objective Response or Adverse Effects: A Retrospective Study

Table 3

Predictive factors associated with relapse in the anti-PD-1 cohort estimated with Cox regression model, University Hospital of Bordeaux, 2019.

Variable	Crude HR (95% CI)	^1	Adjusted HR (95% CI)	^2
Age	0.97 (0.94, 1)	0.065	0.97 (0.93, 1.01)	0.122
Women	2.28 (0.72, 7.2)	0.155	2.21 (0.64, 7.69)	0.211
TOT	0.97 (0.91, 1.04)	0.417	0.94 (0.85, 1.03)	0.178
Reason of discontinuation (ref. = toxicity)		0.445
PR/SD	0.7 (0.14, 3.46)
CR	0.43 (0.11, 1.67)
BRAF_mutation	2.18 (0.7, 6.77)	0.184	1.95 (0.56, 6.80)	0.293
Number of metastasis	1.22 (0.83, 1.78)	0.331
Cerebral metastasis	1.94 (0.58, 6.45)	0.302
High LDH	3.6 (0.72, 17.89)	0.129

¹Crude value, likelihood ratio test; ²adjusted value, likelihood ratio test; TOT: time on treatment; CR: complete response; PR: partial response; SD: stable disease; LDH: lactate dehydrogenase.